Kontermann RE - Search Results

1

Selective Targeting of TNF Receptors as a Novel Therapeutic Approach.

Fischer R, Kontermann RE, Pfizenmaier K. Fischer R, et al. Among authors: kontermann re. Front Cell Dev Biol. 2020 May 26;8:401. doi: 10.3389/fcell.2020.00401. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32528961 Free PMC article. Review.

2

A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.

Kontermann RE, Münkel S, Neumeyer J, Müller D, Branschädel M, Scheurich P, Pfizenmaier K. Kontermann RE, et al. J Immunother. 2008 Apr;31(3):225-34. doi: 10.1097/CJI.0b013e31816a88f9. J Immunother. 2008. PMID: 18317365

3

Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.

Messerschmidt SK, Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K, Landfester K, Kontermann RE. Messerschmidt SK, et al. Among authors: kontermann re. J Control Release. 2009 Jul 1;137(1):69-77. doi: 10.1016/j.jconrel.2009.03.010. Epub 2009 Mar 21. J Control Release. 2009. PMID: 19306900

4

ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody.

Zettlitz KA, Lorenz V, Landauer K, Münkel S, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann R. Zettlitz KA, et al. MAbs. 2010 Nov-Dec;2(6):639-47. doi: 10.4161/mabs.2.6.13583. Epub 2010 Nov 1. MAbs. 2010. PMID: 20935477 Free PMC article.

5

Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.

Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, Nussler AK, Göttsch D, Münkel S, Bantel H, Kontermann RE, Pfizenmaier K. Siegemund M, et al. Among authors: kontermann re. Cell Death Dis. 2012 Apr 12;3(4):e295. doi: 10.1038/cddis.2012.29. Cell Death Dis. 2012. PMID: 22495350 Free PMC article.

6

Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.

Wahl K, Siegemund M, Lehner F, Vondran F, Nüssler A, Länger F, Krech T, Kontermann R, Manns MP, Schulze-Osthoff K, Pfizenmaier K, Bantel H. Wahl K, et al. Hepatology. 2013 Feb;57(2):625-36. doi: 10.1002/hep.26082. Epub 2013 Jan 8. Hepatology. 2013. PMID: 22991197

7

Antagonists of TNF action: clinical experience and new developments.

Kontermann RE, Scheurich P, Pfizenmaier K. Kontermann RE, et al. Expert Opin Drug Discov. 2009 Mar;4(3):279-92. doi: 10.1517/17460440902785167. Expert Opin Drug Discov. 2009. PMID: 23489126

8

Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity.

Richter F, Liebig T, Guenzi E, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE. Richter F, et al. Among authors: kontermann re. PLoS One. 2013 Aug 19;8(8):e72156. doi: 10.1371/journal.pone.0072156. eCollection 2013. PLoS One. 2013. PMID: 23977237 Free PMC article.

9

An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.

Berger V, Richter F, Zettlitz K, Unverdorben F, Scheurich P, Herrmann A, Pfizenmaier K, Kontermann RE. Berger V, et al. Among authors: kontermann re. Protein Eng Des Sel. 2013 Oct;26(10):581-7. doi: 10.1093/protein/gzt044. Epub 2013 Sep 4. Protein Eng Des Sel. 2013. PMID: 24006371

10

Tetravalent antibody-scTRAIL fusion proteins with improved properties.

Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE. Seifert O, et al. Among authors: kontermann re. Mol Cancer Ther. 2014 Jan;13(1):101-11. doi: 10.1158/1535-7163.MCT-13-0396. Epub 2013 Oct 3. Mol Cancer Ther. 2014. PMID: 24092811

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

178 results

Search Page